Structural data of integrin ␣IIb3 have been interpreted as supporting a model in which: 1) the receptor exists primarily in a "bent," low affinity conformation on unactivated platelets and 2) activation induces an extended, high affinity conformation prior to, or following, ligand binding. Previous studies found that "clasping" the ␣IIb head domain to the 3 tail decreased fibrinogen binding. To study the role of ␣IIb extension about the genu, we introduced a disulfide "clamp" between the ␣IIb thigh and calf-1 domains. Clamped ␣IIb3 had markedly reduced ability to bind the large soluble ligands fibrinogen and PAC-1 when activated with monoclonal antibody (mAb) PT25-2 but not when activated by Mn 2؉ or by coexpressing the clamped ␣IIb with a 3 subunit containing the activating mutation N339S. The clamp had little effect on the binding of the snake venom kistrin (M r 7,500) or ␣IIb3-mediated adhesion to immobilized fibrinogen, but it did diminish the enhanced binding of mAb AP5 in the presence of kistrin. Collectively, our studies support a role for ␣IIb extension about the genu in the binding of ligands of 340,000 and 900,000 M r with mAb-induced activation but indicate that it is not an absolute requirement. Our data are consistent with ␣IIb extension resulting in increased access to the ligand-binding site and/or facilitating the conformational change(s) in 3 that affect the intrinsic affinity of the binding pocket for ligand.The platelet ␣IIb3 receptor plays an important role in both hemostasis and thrombosis (1). Ligand binding to ␣IIb3 is controlled by an activation process that affects the conformation of the receptor and ligand binding, in turn, can also affect the conformation of the receptor (2). Several different conformations of ␣IIb3 have been identified based on inferences from biochemical analyses (3), studies employing monoclonal antibodies (4 -7) and electron microscopy (8 -10), comparison of the crystal structures of the liganded ␣IIb3 headpiece (11) and the unliganded complete ectodomain (12), and analysis of the unliganded and liganded ectodomain of the related ␣V3 receptor (13,14). Receptor extension about the regions encompassing the thigh, genu, and calf-1 domains of ␣IIb and the plexin-semaphorin-integrin (PSI), 2 integrin epidermal growth factor-1 (IEGF-1), and IEGF-2 domains of 3 or comparable regions of other integrin receptors has been proposed to play an important role in receptor activation (12,(15)(16)(17)(18), but there is uncertainty about whether this conformational change occurs prior to or after ligand binding (19 -21). Thus, "cross-clasping" the ␣IIb headpiece -propeller domain to the 3 IEGF-4 domain in the tail region via a newly engineered disulfide bond prevented the binding of fibrinogen induced by activating mAb in concert with the activating divalent cation Mn 2ϩ , and a similar effect was observed with cross-clasped ␣V3 (16). In both cases the loss of ligand binding could be rescued by reducing the cross-clasped receptors with dithiothreitol (DTT). In contr...